Mutational Status is Associated with a Higher Rate of Pathologic Complete Response After Neoadjuvant Chemotherapy in Hormone Receptor-Positive Breast Cancer

ConclusionsThis study showed thatBRCA1 mutation carriers with HR+/HER2 − breast cancers have a higher rate of pCR than sporadic cancers and may derive greater benefit from chemotherapy. The use of NAC to downstage these patients should be considered.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research